{"id":"https://genegraph.clinicalgenome.org/r/6c163b7c-73d5-4f2f-994f-3417a43db4f7v1.1","type":"EvidenceStrengthAssertion","dc:description":"SAMD9 was first reported in relation to autosomal dominant SAMD9-related spectrum and myeloid neoplasm risk in 2016 (Narumi et al., PMID: 27182967). SAMD9-related spectrum and myeloid neoplasm risk is a syndromic condition characterized by myelodysplasia, adrenal hypoplasia, growth restriction, genital phenotypes, enteropathy, developmental delay, and dysmorphic features. SAMD9 has been associated with MIRAGE syndrome (OMIM 617053), Monosomy 7 myelodysplasia and leukemia syndrome 2 (OMIM 619041), and Tumoral calcinosis, familial, normophosphatemic (OMIM 610455). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in inheritance pattern, molecular mechanism and phenotypic variability. Therefore, the disease entities have been split into two disease entities by inheritance pattern. The autosomal dominant MIRAGE syndrome and monosomy 7 myelodysplasia and leukemia syndrome 2 were lumped together while the recessive tumoral calcinosis, familial, normophosphatemic was split. This curation addresses SAMD9 in relation to the SAMD9-related spectrum and myeloid neoplasm risk, which includes the autosomal dominant conditions. The spectrum can affect multiple organ systems, particularly endocrine, cardiopulmonary, genitourinary, and gastrointestinal systems, and also include immune deficiency. Sixteen unique missense variants that have been reported in at least 20 probands in 4 publications (PMIDs: 27182967, 28487541, 28346228, 30046003) are included in this curation. More genetic evidence is available in the literature, however, the maximum points for genetic evidence has been reached. The mechanism of pathogenicity appears to be gain-of-function. Of note, there have been two biallelic cases reported in the literature with some features of autosomal dominant SAMD9-related spectrum and myeloid neoplasm risk (PMIDs: 31900929, 37830462). This gene-disease relationship is also supported by experimental evidence including expression data, and functional alteration data in patient cells (PMIDs: 27182967, 2834622). In summary, there is definitive evidence supporting the relationship between SAMD9 and autosomal dominant SAMD9-related spectrum and myeloid neoplasm risk. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Childhood, Adolescent, and Young Adult Cancer Predisposition GCEP on the meeting date December 10th, 2024 (SOP Version 11).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6c163b7c-73d5-4f2f-994f-3417a43db4f7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/217808da-14ba-4447-944c-ed1cd64d4b7e","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/217808da-14ba-4447-944c-ed1cd64d4b7e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10157","date":"2024-12-10T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/217808da-14ba-4447-944c-ed1cd64d4b7e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10157","date":"2025-07-18T16:59:17.865Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/217808da-14ba-4447-944c-ed1cd64d4b7e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c74d0ec7-dc01-431a-8766-aa7b00d6b7e2","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c74d0ec7-dc01-431a-8766-aa7b00d6b7e2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/deec4bd1-f20b-4bf0-b978-9c02201e772a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2945G>A (p.Arg982His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368189192"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/c74d0ec7-dc01-431a-8766-aa7b00d6b7e2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d2e81f75-b866-48b5-b1ec-3312abbcf4fd","type":"EvidenceLine","dc:description":"Recurrent variant","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2e81f75-b866-48b5-b1ec-3312abbcf4fd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/a85c3076-0391-4611-b23d-43e632c318a8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.1376G>A (p.Arg459Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368197084"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d2e81f75-b866-48b5-b1ec-3312abbcf4fd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/499b795d-6abd-44bd-8412-c81675dde3ef","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/499b795d-6abd-44bd-8412-c81675dde3ef_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/89abc257-5d29-4069-a109-1905190bd8ae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2500A>T (p.Asn834Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368190377"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/499b795d-6abd-44bd-8412-c81675dde3ef_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a19e3acb-56cb-4457-85ac-150f5c470227","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a19e3acb-56cb-4457-85ac-150f5c470227_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/3f9b9e9f-4140-4be6-bd91-6d9175e9eae3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2305G>A (p.Asp769Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368191536"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/a19e3acb-56cb-4457-85ac-150f5c470227_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fb90c327-a321-40ed-a30d-ab990a752d48","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb90c327-a321-40ed-a30d-ab990a752d48_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28487541","allele":{"id":"https://genegraph.clinicalgenome.org/r/d8534e2b-ab9d-4c9b-ac34-885b5cd3cd39","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.3406G>C (p.Glu1136Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368185428"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/fb90c327-a321-40ed-a30d-ab990a752d48_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Western blot showed less ERK phosphorylation in 293T cells transiently expressing the mutant GFP-SAMD9 protein when compared to the wild-type following serum stimulation ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f3e709d9-9edc-4d99-9543-af8937b2b6cb","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3e709d9-9edc-4d99-9543-af8937b2b6cb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/095aad51-2953-4fb8-9d8d-6bd9d00fedaf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.3877C>T (p.Arg1293Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368182017"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f3e709d9-9edc-4d99-9543-af8937b2b6cb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/80e9ce4a-fde8-488b-9c94-ce79a10c854d","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/80e9ce4a-fde8-488b-9c94-ce79a10c854d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/c6263144-dd71-4158-bc11-6293459f22e8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.4707G>T (p.Lys1569Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368176098"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/80e9ce4a-fde8-488b-9c94-ce79a10c854d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5f5bf2c4-fd76-4ea4-ad6c-8a5133906893","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f5bf2c4-fd76-4ea4-ad6c-8a5133906893_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/1536b0a8-e656-4ca4-a161-1e14ff80a5e9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2920G>A (p.Glu974Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368189249"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/5f5bf2c4-fd76-4ea4-ad6c-8a5133906893_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ed445853-317e-47dd-9857-f3172334b441","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ed445853-317e-47dd-9857-f3172334b441_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30046003","allele":{"id":"https://genegraph.clinicalgenome.org/r/e61cfb45-de81-4eb2-97d1-9e27ab00efa4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2026A>G (p.Lys676Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368193625"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/ed445853-317e-47dd-9857-f3172334b441_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"HEK293T cells transfected with the variant showed reduced cell cycle progression and almost no proliferation compared to controls, consistent with a gain-of-function effect","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d0c60215-78c0-4bc4-8b6f-23dfaf0af780","type":"EvidenceLine","dc:description":"Recurrent variant","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d0c60215-78c0-4bc4-8b6f-23dfaf0af780_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/095aad51-2953-4fb8-9d8d-6bd9d00fedaf"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d0c60215-78c0-4bc4-8b6f-23dfaf0af780_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b3e5fce6-4796-4898-99a8-dc5be66e2732","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b3e5fce6-4796-4898-99a8-dc5be66e2732_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/4d0a4cdf-4868-48d9-8cae-69172fe8bac2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.3584C>T (p.Ala1195Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368184230"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b3e5fce6-4796-4898-99a8-dc5be66e2732_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b5f4ae24-3044-49f1-b224-afb43bce2e52","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5f4ae24-3044-49f1-b224-afb43bce2e52_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/30187a55-8017-4edd-908e-db53092be50f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.3878G>A (p.Arg1293Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368182011"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b5f4ae24-3044-49f1-b224-afb43bce2e52_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/b4adc16d-a01d-410a-9ac0-fdb61bff7672","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4adc16d-a01d-410a-9ac0-fdb61bff7672_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/ff012db6-2add-485c-b4dd-4093f0cef812","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.3839C>T (p.Pro1280Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368182254"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b4adc16d-a01d-410a-9ac0-fdb61bff7672_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ea4c2034-02a3-4992-8e65-dea44de624f8","type":"EvidenceLine","dc:description":"Recurrent variant","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ea4c2034-02a3-4992-8e65-dea44de624f8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/2567d1c2-5432-41b7-ba4b-059885734c83","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2944C>T (p.Arg982Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368189193"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/ea4c2034-02a3-4992-8e65-dea44de624f8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f8a6fe2d-24d3-4ac5-bef7-1cf66734bba0","type":"EvidenceLine","dc:description":"Recurrent variant","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8a6fe2d-24d3-4ac5-bef7-1cf66734bba0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/a85c3076-0391-4611-b23d-43e632c318a8"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f8a6fe2d-24d3-4ac5-bef7-1cf66734bba0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a4cbc62d-27c9-4179-88c5-3db2d5b601e3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a4cbc62d-27c9-4179-88c5-3db2d5b601e3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/9fccb65d-85e9-401e-94b0-b18edef0e856","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2948T>G (p.Ile983Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368189186"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/a4cbc62d-27c9-4179-88c5-3db2d5b601e3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/efc36e7d-bc7e-4f0b-a268-677a887f8ca1","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/efc36e7d-bc7e-4f0b-a268-677a887f8ca1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/a85c3076-0391-4611-b23d-43e632c318a8"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/efc36e7d-bc7e-4f0b-a268-677a887f8ca1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7adb1e73-6bda-4edc-a1b5-ebc7153430d4","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7adb1e73-6bda-4edc-a1b5-ebc7153430d4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/2567d1c2-5432-41b7-ba4b-059885734c83"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/7adb1e73-6bda-4edc-a1b5-ebc7153430d4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f18efc0d-016f-42d9-be54-da6bc88a2b32","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f18efc0d-016f-42d9-be54-da6bc88a2b32_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","allele":{"id":"https://genegraph.clinicalgenome.org/r/97e0c2af-9758-4224-a42f-c5b4a3769d6e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.3856C>A (p.Gln1286Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA368182157"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f18efc0d-016f-42d9-be54-da6bc88a2b32_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the wt protein in HEK293 cells resulted in mild growth restriction, whereas expression of the variant caused profound growth inhibition, excessively activating the intrinsic growth-restricting function of SAMD9","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ab028dd6-73bb-42d5-9929-2b9c1c00237e","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab028dd6-73bb-42d5-9929-2b9c1c00237e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","allele":{"id":"https://genegraph.clinicalgenome.org/r/396f7584-efd4-4b9e-87a0-302afce33b72","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017654.4(SAMD9):c.2054G>A (p.Arg685Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16618572"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/ab028dd6-73bb-42d5-9929-2b9c1c00237e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of WT SAMD9 in HEK293 cells led to decreased cell proliferation, and transfection of the variant resulted in further repression of cell proliferation, consistent with the variant having a gain-of-function effect","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/217808da-14ba-4447-944c-ed1cd64d4b7e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/217808da-14ba-4447-944c-ed1cd64d4b7e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/58f0872f-c83f-4338-895a-96b6d0847c4c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e7338ec-0369-40c1-9015-77b6febea809","type":"Finding","dc:description":"qrtPCR of human fetal and adult tissues showed SAMD9 expression was highest in the fetal adrenal gland, with high expression also in the colon, bone marrow, fetal liver, thymus, spleen, lung, liver, and fetal testis. This expression pattern correlates very well with the clinical phenotype seen in the patients. Immunohistochemistry of human fetal adrenal tissue showed generalized localization of SAMD9 in the cytoplasm of cells in the definitive and fetal zones, with strong expression in cells positive for the nuclear receptor NR5A1.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","rdfs:label":"Buonocore expression in adrenal gland","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/217808da-14ba-4447-944c-ed1cd64d4b7e_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3fa6dec-e00f-41c5-8731-78b62bf36565","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5762a47e-6d21-4391-9410-0c5a58a16cfc","type":"FunctionalAlteration","dc:description":"The cytoplasm of patient derived cells was filled with giant RAB7A-positive vesicles and the distribution of size for RAB5A-positive vesicles skewed larger in patient-derived cells than in control cells. These abnormalities of the endosome system suggest that the variants in SAMD9 enhance its intrinsic early endosome–fusing activity (that is, the variants are activating). Patient-derived cells grew more slowly than cells from a control individual, although cell cycle parameters and levels of apoptosis were comparable to those in control cells. ERK phosphorylation assays and membrane expression of EGFR showed that mutant cells showed lower levels of pERK and EGFR expression on the plasma membrane than control cells.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27182967","rdfs:label":"Narumi functional alteration"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1dd0bdee-00ca-4aad-8807-dd883c48b70f","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23427965-8bb9-4355-a5e5-f6d152be22db","type":"FunctionalAlteration","dc:description":"Cell proliferation assays were performed in fibroblasts from 3 patients with MIRAGE syndrome. These fibroblasts express the mutated alleles and showed significantly decreased proliferation in comparison with control. Additionally, the SAMD9 protein and mRNA expression in fibroblast samples of these 3 patients showed a reduced expression pattern compared with that of samples from 3 healthy control individuals \n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28346228","rdfs:label":"Buonocore functional alteration "}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5}],"evidenceStrength":"Definitive","sequence":10825,"specifiedBy":"GeneValidityCriteria11","strengthScore":14.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/VQEmdm78vC8","type":"GeneValidityProposition","disease":"obo:MONDO_0100628","gene":"hgnc:1348","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_217808da-14ba-4447-944c-ed1cd64d4b7e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}